Sugi Predict

Sugi Predict / Compounds / SCHEMBL314142

SCHEMBL314142

SCHEMBL314142

CC(C)(C)OC(=O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 2/20 0.58
▸ ALPI P09923 1/20 0.58
▸ PKM P14618 1/20 0.58
▸ PTGS1 P23219 1/20 0.58
▸ XIAP P98170 1/20 0.58
▸ LTA4H P09960 2/20 0.51
▸ SLC15A1 P46059 2/20 0.50
▸ ITGA4 P13612 1/20 0.50
▸ ITGB7 P26010 1/20 0.50
▸ ATM Q13315 1/20 0.48
▸ SLC1A3 P43003 2/20 0.46
▸ SLC1A2 P43004 2/20 0.46
▸ SLC1A1 P43005 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ CTSS P25774 2/20 0.46
▸ CTSL P07711 1/20 0.46
▸ CTSB P07858 1/20 0.46
▸ CTSK P43235 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1221379 1.00 SLC7A5 (0.58) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL594132 1.00 SLC7A5 (0.58) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL594131 0.98 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL237073 0.98 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL237074 0.98 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Acetic Acid SCHEMBL7710564 0.98 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL18321716 0.98 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Benzophenone SCHEMBL1679572 0.93 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Benzophenone SCHEMBL1679294 0.93 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL27782845 0.90 SRR (0.51) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 772 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630588-B2 Bicyclic peptide ligands specific for CD137 BICYCLETX LIMITED (GB) 2026-05-19 — — US claimed
CN-119528812-B Double amino acid-genipin derivative and preparation method and application thereof 广东工业大学 2025-06-03 — — CN claimed
CN-119528812-A Double amino acid-genipin derivative and preparation method and application thereof 广东工业大学 2025-02-28 — — CN claimed
CN-119504883-A Synthesis method of RNA monomer intermediate 2' -fluoro-nucleoside modifier 安徽信佰生物医药科技有限公司 2025-02-25 — — CN claimed
US-20250059236-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 BICYCLETX LIMITED (GB) 2025-02-20 — — US claimed
CN-119241385-A Beta-acyloxy enamide derivative and preparation method and application thereof 江西师范大学 2025-01-03 — — CN claimed
CN-113481228-B Microbial unnatural amino acid introducing system and construction method 中国药科大学 2024-07-19 — — CN claimed
CN-118290421-A Chiral probe compound based on flavin skeleton and preparation and application thereof 西北师范大学 2024-07-05 — — CN claimed
CN-118239879-A Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine 泰山学院 2024-06-25 — — CN claimed
CN-118007135-A Corrosion inhibition method for inhibiting metal corrosion in sulfur-containing medium 福建理工大学 2024-05-10 — — CN claimed
CN-1119340-C Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion ELAND PHARMACEUTICALS CO (US) 2003-08-27 — — CN claimed
CN-1351592-A Acyl derivatives for the treatment of VLA-4 related diseases ELAN PHARM INC (US) 2002-05-29 — — CN claimed
CN-1344274-A Pyroglutamic acid derivatives and related compounds that inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARM INC (US) 2002-04-10 — — CN claimed
CN-1265674-A 4-aminophenylalanine compounds for inhibiting leukocyte adhesion mediated by VLA-4 ELAND PHARMACEUTICALS CO (US) 2000-09-06 — — CN claimed
CN-1265657-A Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion ELAND PHARMACEUTICALS CO (US) 2000-09-06 — — CN claimed
CN-1265668-A Substituted phenylalanine-type compounds that inhibit VLA-4 mediated leukocyte adhesion ELAND PHARMACEUTICALS CO (US) 2000-09-06 — — CN claimed
CN-1265673-A Dipeptide compounds for inhibiting leukocyte adhesion mediated by VLA-4 ELAND PHARMACEUTICALS CO (US) 2000-09-06 — — CN claimed
US-4346039-A Synthesis of ochratoxins IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 1982-08-24 — — US claimed
US-4308168-A ALKYLESTERS OF AMINO ACIDS, NONTOXIC IDEMITSU KOSAN CO., LTD. (JP) 1981-12-29 — — US claimed
US-3978035-A POLYPEPTIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DT) 1976-08-31 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630588-B2 Bicyclic peptide ligands specific for CD137 PTMS, IL36G, HLA-A SLC7A5 236/4885ALPI 2514/4885PKM 4581/4885
US-20250059236-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 CD2BP2, CD40, SDC1 SLC7A5 1031/4885ALPI 4096/4885PKM 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.